Invasive mucinous adenocarcinoma (IMA) is a rare subtype of pulmonary adenocarcinoma, accounting for approximately 2%-10% of all pulmonary adenocarcinoma cases. IMA is characterized by a high frequency of intrapulmonary metastasis and a generally poor prognosis. Clinically, IMA often presents with nonspecific pneumonia-like symptoms. Radiologically, it manifests as multilobar and multifocal consolidations and ground-glass opacities, which significantly overlap with the radiologic features of pneumonia and other benign or malignant tumors. Consequently, IMA is frequently misdiagnosed in clinical practice, and a definitive diagnosis is nearly impossible upon initial presentation, leading to delayed treatment and a poor prognosis. Currently, there is a lack of systematic reviews correlating the clinical manifestations, pathological characteristics, and radiologic features of IMA. This review aims to systematically elucidate the clinical, pathological, and radiologic features of IMA, and thoroughly analyze its diagnostic challenges and key points for differential diagnosis, in order to provide a theoretical basis and practical guidance for the early diagnosis of this disease.

Invasive mucinous adenocarcinoma (IMA) is a rare subtype of pulmonary adenocarcinoma, accounting for approximately 2%-10% of all pulmonary adenocarcinoma cases. IMA is characterized by a high frequency of intrapulmonary metastasis and a generally poor prognosis. Clinically, IMA often presents with nonspecific pneumonia-like symptoms. Radiologically, it manifests as multilobar and multifocal consolidations and ground-glass opacities, which significantly overlap with the radiologic features of pneumonia and other benign or malignant tumors. Consequently, IMA is frequently misdiagnosed in clinical practice, and a definitive diagnosis is nearly impossible upon initial presentation, leading to delayed treatment and a poor prognosis. Currently, there is a lack of systematic reviews correlating the clinical manifestations, pathological characteristics, and radiologic features of IMA. This review aims to systematically elucidate the clinical, pathological, and radiologic features of IMA, and thoroughly analyze its diagnostic challenges and key points for differential diagnosis, in order to provide a theoretical basis and practical guidance for the early diagnosis of this disease.

Invasive mucinous adenocarcinoma (IMA) is a rare subtype of pulmonary adenocarcinoma, accounting for approximately 2%-10% of all pulmonary adenocarcinoma cases. IMA is characterized by a high frequency of intrapulmonary metastasis and a generally poor prognosis. Clinically, IMA often presents with nonspecific pneumonia-like symptoms. Radiologically, it manifests as multilobar and multifocal consolidations and ground-glass opacities, which significantly overlap with the radiologic features of pneumonia and other benign or malignant tumors. Consequently, IMA is frequently misdiagnosed in clinical practice, and a definitive diagnosis is nearly impossible upon initial presentation, leading to delayed treatment and a poor prognosis. Currently, there is a lack of systematic reviews correlating the clinical manifestations, pathological characteristics, and radiologic features of IMA. This review aims to systematically elucidate the clinical, pathological, and radiologic features of IMA, and thoroughly analyze its diagnostic challenges and key points for differential diagnosis, in order to provide a theoretical basis and practical guidance for the early diagnosis of this disease.

Apoptosis plays a critical role in tumor genesis and progression. Induction of cancer cell apoptosis with traditional Chinese medicines is at present a hot topic in the research of cancer therapy. It has been found that many active components of traditional Chinese medicines can induce cancer cell apoptosis; ginsenoside and oridonin are two of them that have been studied relatively thoroughly. The mechanisms that ginsenoside and oridonin induce cancer cell apoptosis include arresting cell cycle progression, up-regulating expression of apoptotic promoting proteins, down-regulating expression of apoptotic inhibiting proteins, and activating caspase cascade.